2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1419

Infections Increase Risk of Arterial and Venous Thromboses in Systemic Lupus Erythematosus Patients: 4925 Patient Years of Follow-up
Abstract Number: 195

Inflammatory Arthritis in Patients with Myelodysplastic Syndrome: French Multicenter Retrospective Study
Abstract Number: 1398

Inflammatory Back Pain Is Increased in SLE and Associated with Anti-Sm Antibodies
Abstract Number: 1350

Inflammatory Biomarkers in Psoriatic Arthritis
Abstract Number: 629

Inflammatory Biomarkers of Atherosclerosis and Oxidative Stress Are Associated with Disease Flare in SLE
Abstract Number: 1267

Inflammatory Burden Predicts Progression of Carotid Plaque in Rheumatoid Arthritis: A 24-Month Longitudinal Analysis
Abstract Number: 1927

Inflammatory Meningeal Involvement in Patients with Rheumatic Diseases Responsive to Rituximab
Abstract Number: 214

Inflammatory Muscle Disease Associated Pulmonary Hypertension – Clinical Features and Survival At a National Referral Centre
Abstract Number: 2033

Infliximab Is an Effective Therapy in Pediatric Renal Sarcoidosis
Abstract Number: 1373

Influence of Early Onset On the Clinical Characteristics and Prognosis of Ankylosing Spondylitis
Abstract Number: 424

Influence of Pregnancy On Disease Activity-Associated Genes in Rheumatoid Arthritis
Abstract Number: 1931

Influence of Trough Serum Drug Level and Immunogenicity On the Lack of Response to Adalimumab Therapy in Inflammatory Bowel Disease Patients
Abstract Number: 1139

Inhaled Nitrous Oxide Facilitates Access to Intra-Articular Corticosteroid Injections in Children with Juvenile Idiopathic Arthritis
Abstract Number: 1452

Inherent Strain-Based Differences in Qualitative CD4 T Cell Responses Determine Lupus Severity
Abstract Number: 1448

Inhibition of Calcium/Calmodulin-Dependent Protein Kinase IV Suppresses the Autoimmunity in Lupus-Prone Mice

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].